ACROBiosystems Secures PMDA Approval for GMP-Grade IL-15

The PMDA confirmation, designated as 薬機審長発第47号, signals that the recombinant human IL-15 protein meets rigorous safety benchmarks. By verifying that the material is free from human or animal-derived components and toxic substances, the agency has effectively pre-cleared the cytokine for use in high-stakes immunotherapy production, including CAR-T, CAR-NK, and TCR-T cell therapies. For developers, this creates a streamlined pathway for regulatory submission, as they can now reference ACROBiosystems’ established compliance data rather than conducting independent, time-consuming raw material audits.

Beyond administrative efficiency, the protein serves a technical function in immune cell culture. It activates the JAK-STAT and PI3K-AKT signaling pathways, which enhances the cytotoxic activity and long-term persistence of T cells. By fostering the expansion of stem cell-like memory T cells and memory NK cells, the product addresses common hurdles in cell therapy such as rapid cell exhaustion. This milestone aligns with ACROBiosystems' broader regulatory strategy, which includes FDA DMF filings and comprehensive support files for global markets, further cementing the company’s role in the international biopharmaceutical supply chain.